Sionna Therapeutics, Inc. (SION)
Sionna Therapeutics, Inc. (SION)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -26,779 | -20,440 | -20,278 | -34,550 |
| Stock-based compensation expense | 6,553 | 3,826 | 3,306 | 4,934 |
| Non-cash operating lease expense | 489 | 491 | 490 | 981 |
| Amortization of discount on marketable securities | 200 | 353 | 836 | 1,863 |
| Non-cash expense related to ipr&d acquisition | NaN | 0 | 0 | NaN |
| Depreciation expense | 154 | 152 | 189 | 306 |
| Prepaid expenses and other current assets | -740 | 1,539 | -177 | 720 |
| Accounts payable | 1,209 | -712 | 567 | -272 |
| Other assets | NaN | 0 | 0 | 0 |
| Accrued expenses and other current liabilities | -3,463 | 2,492 | 1,684 | -2,201 |
| Operating lease liabilities | -543 | -543 | -529 | -1,056 |
| Net cash used in operating activities | -21,840 | -16,626 | -15,230 | -34,441 |
| Purchases of property and equipment | 0 | 204 | 87 | 86 |
| Purchases of marketable securities | 25,327 | 42,878 | 54,136 | 228,011 |
| Maturities of marketable securities | 50,147 | 65,670 | 77,325 | 63,658 |
| Proceeds from issuance of series c convertible preferred stock, net of issuance costs | NaN | 0 | 0 | 0 |
| Net cash provided by (used in) investing activities | 24,820 | 22,588 | 23,102 | -164,439 |
| Proceeds from initial public offering, net of underwriter discounts, commissions and offering costs paid during the period | 0 | 0 | 0 | 202,071 |
| Payment of deferred offering costs | 320 | 0 | 0 | NaN |
| Exercise of common stock options | 2,213 | 1,659 | 1,974 | 6 |
| Net cash provided by financing activities | 1,893 | 1,659 | 1,974 | 202,077 |
| Net increase in cash, cash equivalents and restricted cash | 4,873 | 7,621 | 9,846 | 3,197 |
| Cash, cash equivalents and restricted cash at beginning of period | 59,414 | 51,793 | 38,750 | NaN |
| Cash, cash equivalents and restricted cash at end of period | 64,287 | 59,414 | 51,793 | NaN |